We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is AxoGen (AXGN) Outperforming Other Medical Stocks This Year?
Read MoreHide Full Article
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Is AxoGen (AXGN - Free Report) one of those stocks right now? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
AxoGen is one of 916 companies in the Medical group. The Medical group currently sits at #8 within the Zacks Sector Rank. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. AxoGen is currently sporting a Zacks Rank of #2 (Buy).
Within the past quarter, the Zacks Consensus Estimate for AXGN's full-year earnings has moved 2.2% higher. This shows that analyst sentiment has improved and the company's earnings outlook is stronger.
According to our latest data, AXGN has moved about 50.5% on a year-to-date basis. Meanwhile, stocks in the Medical group have gained about 5.8% on average. This means that AxoGen is outperforming the sector as a whole this year.
BioCryst Pharmaceuticals (BCRX - Free Report) is another Medical stock that has outperformed the sector so far this year. Since the beginning of the year, the stock has returned 7.3%.
For BioCryst Pharmaceuticals, the consensus EPS estimate for the current year has increased 11.5% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
To break things down more, AxoGen belongs to the Medical - Instruments industry, a group that includes 78 individual companies and currently sits at #148 in the Zacks Industry Rank. Stocks in this group have gained about 0.1% so far this year, so AXGN is performing better this group in terms of year-to-date returns.
BioCryst Pharmaceuticals, however, belongs to the Medical - Drugs industry. Currently, this 133-stock industry is ranked #81. The industry has moved -3.2% so far this year.
Investors with an interest in Medical stocks should continue to track AxoGen and BioCryst Pharmaceuticals. These stocks will be looking to continue their solid performance.
View the Zacks #1 Rank List
Image: Bigstock
Is AxoGen (AXGN) Outperforming Other Medical Stocks This Year?
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Is AxoGen (AXGN - Free Report) one of those stocks right now? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
AxoGen is one of 916 companies in the Medical group. The Medical group currently sits at #8 within the Zacks Sector Rank. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. AxoGen is currently sporting a Zacks Rank of #2 (Buy).
Within the past quarter, the Zacks Consensus Estimate for AXGN's full-year earnings has moved 2.2% higher. This shows that analyst sentiment has improved and the company's earnings outlook is stronger.
According to our latest data, AXGN has moved about 50.5% on a year-to-date basis. Meanwhile, stocks in the Medical group have gained about 5.8% on average. This means that AxoGen is outperforming the sector as a whole this year.
BioCryst Pharmaceuticals (BCRX - Free Report) is another Medical stock that has outperformed the sector so far this year. Since the beginning of the year, the stock has returned 7.3%.
For BioCryst Pharmaceuticals, the consensus EPS estimate for the current year has increased 11.5% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
To break things down more, AxoGen belongs to the Medical - Instruments industry, a group that includes 78 individual companies and currently sits at #148 in the Zacks Industry Rank. Stocks in this group have gained about 0.1% so far this year, so AXGN is performing better this group in terms of year-to-date returns.
BioCryst Pharmaceuticals, however, belongs to the Medical - Drugs industry. Currently, this 133-stock industry is ranked #81. The industry has moved -3.2% so far this year.
Investors with an interest in Medical stocks should continue to track AxoGen and BioCryst Pharmaceuticals. These stocks will be looking to continue their solid performance.